BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS(TM) Patient

Executive Summary

• First patient in the Bria‑OTS Phase 1/2a metastatic breast cancer trial achieved a durable, complete resolution of a lung metastasis, confirmed at 2, 4, 6 and now 11 months post‑treatment.
• The patient received 17 cycles of Bria‑OTS monotherapy over a 12‑month study period with no treatment‑limiting toxicities reported and stable disease at all other evaluable sites.
• Phase 1 dose escalation is complete; Phase 2a combination dosing (Bria‑OTS + immune checkpoint inhibitor) is now underway.

Key Details

• Patient Profile: 78‑year‑old woman, hormone‑receptor positive (HR+), HER2‑negative metastatic breast cancer with multiple prior treatment failures.
• Therapy Administered: Bria‑OTS personalized off‑the‑shelf immunotherapy, monotherapy; total of 17 cycles administered over 12 months.
• Efficacy Outcome: 100 % resolution of a right‑lung metastasis observed at 2 months and confirmed at 4, 6, and 11 months (Figure 1). No new lesions; other disease sites remained stable.
• Safety Profile: No treatment‑limiting toxicities reported throughout the dosing period.
• Study Status: Phase 1 dose escalation completed; Phase 2a expansion now evaluating Bria‑OTS in combination with an immune checkpoint inhibitor.
• Regulatory Identifiers: ClinicalTrials.gov NCT06471673 (Phase 1/2a metastatic recurrent breast cancer).

Notable Quotes

“The sustained clinical response observed in this late‑stage MBC patient, who had previously progressed through multiple prior treatments is remarkable,” – Neal S. Chawla, MD, Principal Investigator, Bria‑OTS study.

“These clinical findings reinforce our confidence in the therapeutic potential and safety of the Bria‑OTS platform,” – Dr. William V. Williams, President & CEO, BriaCell Therapeutics Corp.